Abstract
Although potentially curative therapies for hepatocellular carcinoma (HCC) are well established, they are offered only to a limited number of patients. For advanced HCC, sorafenib is now the treatment of choice. Radiotherapy technology has evolved remarkably during the past decade and can be precisely delivered, thereby permitting higher doses to the tumor and reduced doses to surrounding normal tissues. According to the Korean Liver Cancer Study Group (KLCSG) practice guidelines, radiation therapy is considered appropriate for unresectable, locally advanced HCC without extrahepatic metastasis, Child-Pugh class A or B, and tumors occupying less than two thirds of the liver with level II evidence. In this review, we discuss the radiotherapeutic strategies for each clinical setting in patients with HCC.
| Original language | English |
|---|---|
| Pages (from-to) | 123-133 |
| Number of pages | 11 |
| Journal | Oncology |
| Volume | 81 |
| Issue number | SUPPL. 1 |
| DOIs | |
| Publication status | Published - 2011 Dec 1 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Oncology
- Cancer Research
Cite this
}
Radiotherapeutic strategies in the management of hepatocellular carcinoma. / Lee, Ik Jae; Seong, Jinsil.
In: Oncology, Vol. 81, No. SUPPL. 1, 01.12.2011, p. 123-133.Research output: Contribution to journal › Review article
TY - JOUR
T1 - Radiotherapeutic strategies in the management of hepatocellular carcinoma
AU - Lee, Ik Jae
AU - Seong, Jinsil
PY - 2011/12/1
Y1 - 2011/12/1
N2 - Although potentially curative therapies for hepatocellular carcinoma (HCC) are well established, they are offered only to a limited number of patients. For advanced HCC, sorafenib is now the treatment of choice. Radiotherapy technology has evolved remarkably during the past decade and can be precisely delivered, thereby permitting higher doses to the tumor and reduced doses to surrounding normal tissues. According to the Korean Liver Cancer Study Group (KLCSG) practice guidelines, radiation therapy is considered appropriate for unresectable, locally advanced HCC without extrahepatic metastasis, Child-Pugh class A or B, and tumors occupying less than two thirds of the liver with level II evidence. In this review, we discuss the radiotherapeutic strategies for each clinical setting in patients with HCC.
AB - Although potentially curative therapies for hepatocellular carcinoma (HCC) are well established, they are offered only to a limited number of patients. For advanced HCC, sorafenib is now the treatment of choice. Radiotherapy technology has evolved remarkably during the past decade and can be precisely delivered, thereby permitting higher doses to the tumor and reduced doses to surrounding normal tissues. According to the Korean Liver Cancer Study Group (KLCSG) practice guidelines, radiation therapy is considered appropriate for unresectable, locally advanced HCC without extrahepatic metastasis, Child-Pugh class A or B, and tumors occupying less than two thirds of the liver with level II evidence. In this review, we discuss the radiotherapeutic strategies for each clinical setting in patients with HCC.
UR - http://www.scopus.com/inward/record.url?scp=84855336704&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84855336704&partnerID=8YFLogxK
U2 - 10.1159/000333275
DO - 10.1159/000333275
M3 - Review article
VL - 81
SP - 123
EP - 133
JO - Oncology
JF - Oncology
SN - 0030-2414
IS - SUPPL. 1
ER -